One of the key developments of the past two decades is the rise of the emerging middle class—nations of lower-middle income and upper-middle class consumers with an average per capita income between $1,000 and $12,000. Globally, this group accounts for an estimated $300 billion pharmaceutical market.
These consumers offer life sciences companies extensive market opportunities. But how successful companies will be in these markets depends on how they position their supply chains to gain the best patient access possible.
Comment submitted
Submitted comment may not display automatically.